23 research outputs found
Effectiveness of Risk Evaluation and Mitigation Strategies (REMS) for Lenalidomide and Thalidomide: Patient Comprehension and Knowledge Retention
Trapping \u3ci\u3ePhyllophaga \u3c/i\u3espp. (Coleoptera: Scarabaeidae: Melolonthinae) in the United States and Canada using sex attractants.
The sex pheromone of the scarab beetle, Phyllophaga anxia, is a blend of the methyl esters of two amino acids, L-valine and L-isoleucine. A field trapping study was conducted, deploying different blends of the two compounds at 59 locations in the United States and Canada. More than 57,000 males of 61 Phyllophaga species (Coleoptera: Scarabaeidae: Melolonthinae) were captured and identified. Three major findings included: (1) widespread use of the two compounds [of the 147 Phyllophaga (sensu stricto) species found in the United States and Canada, males of nearly 40% were captured]; (2) in most species intraspecific male response to the pheromone blends was stable between years and over geography; and (3) an unusual pheromone polymorphism was described from P. anxia. Populations at some locations were captured with L-valine methyl ester alone, whereas populations at other locations were captured with L-isoleucine methyl ester alone. At additional locations, the L-valine methyl ester-responding populations and the L-isoleucine methyl ester-responding populations were both present, producing a bimodal capture curve. In southeastern Massachusetts and in Rhode Island, in the United States, P. anxia males were captured with blends of L-valine methyl ester and L-isoleucine methyl ester
Risk Factors for Venous Thromboembolism and the Use of Antithrombotic Prophylaxis in Multiple Myeloma Patients Treated with Lenalidomide and Dexamethasone Combination Regimens.
Erythema Multiforme/Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis in Lenalidomide-Treated Patients
Validating an algorithm for multiple myeloma based on administrative data using a SEER tumor registry and medical record review
PURPOSE: Large numbers of multiple myeloma patients can be studied in real-world clinical settings using administrative databases. The validity of these studies is contingent upon accurate case identification. Our objective was to develop and evaluate algorithms to use with administrative data to identify multiple myeloma cases.
METHODS: Patients aged ≥18 years with ≥1 International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) code for multiple myeloma (203.0x) were identified at two study sites. At site 1, several algorithms were developed and validated by comparing results to tumor registry cases. An algorithm with a reasonable positive predictive value (PPV) (0.81) and sensitivity (0.73) was selected and then validated at site 2 where results were compared with medical chart data. The algorithm required that ICD-9-CM codes 203.0x occur before and after the diagnostic procedure codes for multiple myeloma.
RESULTS: At site 1, we identified 1432 patients. The PPVs of algorithms tested ranged from 0.54 to 0.88. Sensitivities ranged from 0.30 to 0.88. At site 2, a random sample (n = 400) was selected from 3866 patients, and medical charts were reviewed by a clinician for 105 patients. Algorithm PPV was 0.86 (95% CI, 0.79-0.92).
CONCLUSIONS: We identified cases of multiple myeloma with adequate validity for claims database analyses. At least two ICD-9-CM diagnosis codes 203.0x preceding diagnostic procedure codes for multiple myeloma followed by ICD-9-CM codes within a specific time window after diagnostic procedure codes were required to achieve reasonable algorithm performance
A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide
A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide
In a retrospective pooled analysis of 11 clinical trials of
lenalidomide-based therapy for relapsed/refractory multiple myeloma (MM;
N = 3846), the overall incidence rate (IR, events per 100 patient-years)
of second primary malignancies (SPMs) was 3.62. IR of invasive
(hematologic and solid tumor) SPMs was 2.08, consistent with the
background incidence of developing cancer. In a separate analysis of
pooled data from pivotal phase 3 trials of relapsed or refractory MM (N
= 703), the overall IR of SPMs was 3.98 (95% confidence interval
[CI], 2.51-6.31) with lenalidomide/dexamethasone and 1.38 (95% CI,
0.44-4.27) with placebo/dexamethasone; IRs of nonmelanoma skin cancers
were 2.40 (95% CI, 1.33-4.33) and 0.91 (95% CI, 0.23-3.66),
respectively; IRs of invasive SPMs were 1.71 (95% CI, 0.86-3.43) and
0.91 (95% CI, 0.23-3.66), respectively. The risk of SPMs must be taken
into account before initiating lenalidomide treatment. In the context of
the observed survival benefit in relapsed or refractory MM patients, the
benefit/risk profile of lenalidomide/dexamethasone remains positive.
(Blood. 2012; 119(12): 2764-2767
A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide
In a retrospective pooled analysis of 11 clinical trials of
lenalidomide-based therapy for relapsed/refractory multiple myeloma (MM;
N = 3846), the overall incidence rate (IR, events per 100 patient-years)
of second primary malignancies (SPMs) was 3.62. IR of invasive
(hematologic and solid tumor) SPMs was 2.08, consistent with the
background incidence of developing cancer. In a separate analysis of
pooled data from pivotal phase 3 trials of relapsed or refractory MM (N
= 703), the overall IR of SPMs was 3.98 (95% confidence interval
[CI], 2.51-6.31) with lenalidomide/dexamethasone and 1.38 (95% CI,
0.44-4.27) with placebo/dexamethasone; IRs of nonmelanoma skin cancers
were 2.40 (95% CI, 1.33-4.33) and 0.91 (95% CI, 0.23-3.66),
respectively; IRs of invasive SPMs were 1.71 (95% CI, 0.86-3.43) and
0.91 (95% CI, 0.23-3.66), respectively. The risk of SPMs must be taken
into account before initiating lenalidomide treatment. In the context of
the observed survival benefit in relapsed or refractory MM patients, the
benefit/risk profile of lenalidomide/dexamethasone remains positive.
(Blood. 2012; 119(12): 2764-2767